转移性骨肉瘤治疗靶点的分子改变：文献复习。
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.
机构信息
Department of Orthopaedic Surgery, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
出版信息
Clin Exp Metastasis. 2011 Jun;28(5):493-503. doi: 10.1007/s10585-011-9384-x. Epub 2011 Apr 2.
Abstract
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy and targeting these features might enhance the efficacy of current treatment. A detailed study of the biological characteristics and behaviour of metastatic OS cells may provide a rational basis for innovative treatment strategies. The aim of this review is to give an overview of the biological changes in metastatic OS cells and the preclinical and clinical efforts targeting the different steps in OS metastases and how these contribute to designing a metastasis directed treatment for OS.
摘要
治疗转移性骨肉瘤（OS）仍然是肿瘤学的一个挑战。目前的治疗策略针对的是原发肿瘤，而不是转移灶，并且在转移性疾病的治疗中疗效有限。转移性细胞具有使其对治疗的敏感性降低的特定特征，针对这些特征可能会提高当前治疗的疗效。对转移性 OS 细胞的生物学特征和行为进行详细研究，可为创新治疗策略提供合理依据。本文综述的目的在于概述转移性 OS 细胞的生物学变化，以及针对 OS 转移不同步骤的临床前和临床努力，以及这些努力如何有助于设计针对 OS 的转移性治疗。
相似文献
1
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature.转移性骨肉瘤治疗靶点的分子改变：文献复习。
Clin Exp Metastasis. 2011 Jun;28(5):493-503. doi: 10.1007/s10585-011-9384-x. Epub 2011 Apr 2.
2
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.组蛋白去乙酰化酶抑制剂伏立诺他可降低骨肉瘤细胞的体外转移行为。
Biomed Res Int. 2015;2015:290368. doi: 10.1155/2015/290368. Epub 2015 Feb 17.
3
Review of the molecular pathogenesis of osteosarcoma.骨肉瘤分子发病机制综述。
Asian Pac J Cancer Prev. 2014;15(15):5967-76. doi: 10.7314/apjcp.2014.15.15.5967.
4
Role of TKI for Metastatic Osteogenic Sarcoma.TKI 在转移性成骨肉瘤中的作用。
Curr Treat Options Oncol. 2020 Jun 29;21(8):65. doi: 10.1007/s11864-020-00760-w.
5
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.骨肉瘤分子靶向治疗的当前进展与未来展望
Int J Mol Sci. 2016 Apr 6;17(4):506. doi: 10.3390/ijms17040506.
6
Metastatic osteosarcoma: a curable advanced malignancy.转移性骨肉瘤：一种可治愈的晚期恶性肿瘤。
J Clin Oncol. 2004 Dec 15;22(24):5017; author reply 5017-8. doi: 10.1200/JCO.2004.04.234.
7
Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.肢体骨肉瘤伴同步肺转移的新辅助化疗：顺铂、阿霉素、大剂量甲氨蝶呤和异环磷酰胺治疗。
Oncol Rep. 2000 Mar-Apr;7(2):339-46. doi: 10.3892/or.7.2.339.
8
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.Fas/FasL 信号通路：在转移过程中的作用及其作为治疗骨肉瘤肺转移的靶点。
Adv Exp Med Biol. 2020;1258:177-187. doi: 10.1007/978-3-030-43085-6_12.
9
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis.IL-6 和 CXCL8 介导骨肉瘤-肺相互作用，对转移至关重要。
JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.99791.
10
Is CDK9 a promising target for both primary and metastatic osteosarcoma?细胞周期蛋白依赖性激酶9（CDK9）是原发性和转移性骨肉瘤的一个有前景的靶点吗？
EBioMedicine. 2019 Feb;40:27-28. doi: 10.1016/j.ebiom.2019.01.016. Epub 2019 Jan 14.
引用本文的文献
1
Whole‑exome evolutionary profiling of osteosarcoma uncovers metastasis‑related driver mutations and generates an independently validated predictive classifier.骨肉瘤的全外显子组进化分析揭示了与转移相关的驱动突变，并生成了一个经独立验证的预测分类器。
J Transl Med. 2025 Jul 7;23(1):746. doi: 10.1186/s12967-025-06796-6.
2
Sulforaphane's Role in Osteosarcoma Treatment: A Systematic Review and Meta-Analysis of Preclinical Studies.萝卜硫素在骨肉瘤治疗中的作用：临床前研究的系统评价和荟萃分析
Biomedicines. 2025 Apr 25;13(5):1048. doi: 10.3390/biomedicines13051048.
3
Whole-Exome Analysis and Osteosarcoma: A Game Still Open.全外显子组分析与骨肉瘤：游戏仍在继续。
Int J Mol Sci. 2024 Dec 20;25(24):13657. doi: 10.3390/ijms252413657.
4
Employing splice-switching oligonucleotides and AAVrh74.U7 snRNA to target insulin receptor splicing and cancer hallmarks in osteosarcoma.利用剪接转换寡核苷酸和AAVrh74.U7小核RNA靶向骨肉瘤中的胰岛素受体剪接和癌症特征。
Mol Ther Oncol. 2024 Nov 23;32(4):200908. doi: 10.1016/j.omton.2024.200908. eCollection 2024 Dec 19.
5
Successful treatment of osteosarcoma in a pregnant woman with survival of the gestational product: A case report and literature review.成功治疗一名怀有存活妊娠产物的孕妇骨肉瘤：病例报告及文献综述
Med Int (Lond). 2024 Oct 9;4(6):73. doi: 10.3892/mi.2024.197. eCollection 2024 Nov-Dec.
6
Comprehensive analysis of splicing factor SRs-related gene characteristics: predicting osteosarcoma prognosis and immune regulation status.剪接因子SRs相关基因特征的综合分析：预测骨肉瘤预后及免疫调节状态
Front Oncol. 2024 Sep 2;14:1456986. doi: 10.3389/fonc.2024.1456986. eCollection 2024.
7
The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.骨肿瘤 microRNAs 全景：近期研究全面综述。
Microrna. 2024;13(3):175-201. doi: 10.2174/0122115366298799240625115843.
8
A bibliometric analysis based on hotspots and frontier trends of positron emission tomography/computed tomography utility in bone and soft tissue sarcoma.基于正电子发射断层扫描/计算机断层扫描在骨与软组织肉瘤应用中的热点和前沿趋势的文献计量分析
Front Oncol. 2024 Jun 21;14:1344643. doi: 10.3389/fonc.2024.1344643. eCollection 2024.
9
Clemastine and hyperthermia enhance sensitization of osteosarcoma cells for apoptosis.氯马斯汀与热疗增强骨肉瘤细胞对凋亡的敏感性。
Mol Cell Oncol. 2024 May 14;11(1):2351622. doi: 10.1080/23723556.2024.2351622. eCollection 2024.
10
Lipid Peroxidation-Related Redox Signaling in Osteosarcoma.骨肉瘤中与脂质过氧化相关的氧化还原信号传导
Int J Mol Sci. 2024 Apr 22;25(8):4559. doi: 10.3390/ijms25084559.
本文引用的文献
1
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts.R1507，一种针对 IGF-1R 的全人源单克隆抗体，单独使用以及与雷帕霉素联合使用均可有效抑制骨肉瘤异种移植物的生长。
Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75. doi: 10.1002/pbc.22479.
2
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth.细胞外基质：休眠到转移生长转变过程中的守门员。
Eur J Cancer. 2010 May;46(7):1181-8. doi: 10.1016/j.ejca.2010.02.027. Epub 2010 Mar 19.
3
How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize.NOTCH信号通路如何促进骨肉瘤细胞的转移能力。
Cancer Treat Res. 2009;152:479-96. doi: 10.1007/978-1-4419-0284-9_28.
4
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.Wnt 抑制因子 1 可降低骨肉瘤的肿瘤生成和转移。
Mol Cancer Ther. 2010 Mar;9(3):731-41. doi: 10.1158/1535-7163.MCT-09-0147. Epub 2010 Mar 2.
5
Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.骨肉瘤细胞中信号转导子和转录激活子 3（Stat3）途径的激活及磷酸化 Stat3 的过表达与不良预后相关。
J Orthop Res. 2010 Jul;28(7):971-8. doi: 10.1002/jor.21088.
6
Targeted therapies in bone sarcomas.骨肉瘤的靶向治疗。
Curr Cancer Drug Targets. 2009 Nov;9(7):843-53. doi: 10.2174/156800909789760410.
7
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.索拉非尼通过潜在抑制 ERK1/2、MCL-1 和 ezrin 通路，在骨肉瘤的临床前模型中阻断肿瘤生长、血管生成和转移潜能。
Mol Cancer. 2009 Dec 10;8:118. doi: 10.1186/1476-4598-8-118.
8
The role of interferons in the treatment of osteosarcoma.干扰素在骨肉瘤治疗中的作用。
Pediatr Blood Cancer. 2010 Mar;54(3):350-4. doi: 10.1002/pbc.22136.
9
Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.常规高级别骨肉瘤中失活的 Wnt/β-连环蛋白通路。
J Pathol. 2010 Jan;220(1):24-33. doi: 10.1002/path.2628.
10
Src kinases as therapeutic targets for cancer.Src激酶作为癌症的治疗靶点。
Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. doi: 10.1038/nrclinonc.2009.129.
Zotero 插件